Affiliations: Centocor Research & Development Inc., 145 King of Prussia Rd., Radnor, PA 19087, USA
Correspondence:
[*]
Corresponding author: Centocor Research & Development Inc. 145 King of Prussia Rd., Radnor, PA 19087, USA. Tel.: +1 610 651 6223; Fax: +1 610 240 8150; E-mail: [email protected]
Abstract: The generation of anti-variable region monoclonal antibodies (mAbs) against therapeutic antibodies is essential in the pharmacokinetic/pharmacodynamic (PK/PD) assessments of the drugs in clinical study samples. Sandwich EIA and other methods are typically employed to achieve sensitivity and selectivity for the PK/PD analyses. These assays usually require generation of mAb reagents that bind specifically to the drug in non-competing pair combinations. Thus, large panels of anti-variable region mAbs must be generated in an expeditious manner to increase the probability of success. Herein we describe a novel immunization method that utilizes type 1 interferons (IFNs) as immunomodulators coupled with an agonistic anti-CD40 mAb as a B cell proliferative agent to drive immune responses. This novel protocol allows for rapid and robust mAb reagent generation without the use of conventional protein-denaturing adjuvants. The use of IFNs allowed for the generation of comparable and in some cases, increased numbers of anti-variable region mAbs in a dramatically shorter timeframe. This IFN based, immunostimulatory approach utilizing a non-denaturing adjuvant, likely presents conformational epitopes and may optimize the humoral response for the rapid generation of anti-variable region reagents to therapeutic mAb candidates.
Keywords: Adjuvant, antibody secreting cell, anti-variable region monoclonal antibodies, B cell proliferative agent, hybridoma, interferons
